Tag:
Merck Serono
Latest Headlines
Latest Headlines
Merck KGaA reveals $385M in cuts as Geneva protests continue
Merck Serono employees in Geneva may have won a battle, but do they have any hope of winning the war?
Serono workers threaten strike against HQ shutdown
The staid streets of Geneva have been crawling with Merck Serono protesters, as local employees marched against the impending shutdown of their headquarters.
Merck Serono to cut 580 Swiss jobs, close Geneva HQ
Whatever its description, the German Merck's decision to shutter its Serono division's Geneva headquarters and cut up to 580 Swiss jobs is a big move to counter recent R&D setbacks.
Merck KGaA shuttering Swiss complex, dispatching R&D to Boston
Once again a big pharma company is restructuring in the wake of a dismal R&D record. And once again the Boston research hub is coming out ahead in the deal.
Merck KGaA manufacturing dodges worst of reductions
The company is closing its Merck Serono headquarters in Geneva, Switzerland, and will eliminate 500 positions and transfer another 750 to locations around the world.
Cost and job cuts coming soon to Merck KGaA
Germany's Merck recently hinted at coming cost cuts, acknowledging development setbacks would force the company to recalibrate.
Bioject mulls options including possible sale
Bioject Medical Technologies ( $BJCT ) has hired a financial adviser to explore the always-ominous "strategic alternatives." One option for the maker of needle-free drug delivery systems:...
Hot Ablynx antibody tech earns $69M discovery pact with Merck Serono
Just days after a rapidly downsizing Pfizer offloaded a partnership with Belgium's Ablynx on its hot nanobody technology, Merck Serono has stepped up to the plate with a fresh $28 million upfront
Biotie backs out of $63M Newron Pharma buyout
Newron Pharmaceuticals has been left at the altar. Finland's Biotie has decided to nix plans to acquire Newron after Merck Serono decided to give up rights to Newron's Parkinson's drug and lead
Merck Serono returns rights to Parkinson's drug to Newron
Merck Serono has decided that the experimental Parkinson's disease drug safinamide won't be as strong a commercial drug as once thought. The company, a unit of Germany's Merck KGaA, has handed back
